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Abstract. The specific mechanisms underlying paraquat
(PQ)‑induced lung injury remain unknown, which limits
understanding of its cytotoxic potential. Although oxidative stress has been established as an important mechanism
underlying PQ toxicity, multiple antioxidants have proven
ineffective in attenuating the deleterious effects of PQ.
Adiponectin, which shows anti‑oxidative and antinitrative effects, may have the potential to reduce PQ‑mediated
injury. The present study determined the protective action
of globular domain adiponectin (gAd) on PQ‑induced lung
injury, and attempted to elucidate the underlying mechanism
or mechanisms of action. BALB/c mice were administered
PQ, with and without 12 or 36 h of gAd pre‑treatment.
The pulmonary oxidative/nitrative status was assessed
by measuring pulmonary O 2 •‑, superoxide dismutase
(SOD), malondialdehyde (MDA), nitric oxide (NO) and
8‑hydroxy‑2‑dydeoxy guanosine (8‑OHdG) production,
and blood 3‑Nitrotyrosine (3‑NT). At a dose of 20 mg/kg,
PQ markedly increased O2•‑, SOD, MDA, NO and 8‑OHdG
production 3 h post‑administration, but did not significantly
increase 3‑NT levels until 12 h. gAd inhibited these changes
in a dose‑dependent manner, via transient activation of MDA,
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followed by attenuation of MDA formation from 6 h onwards.
Histological analysis demonstrated that gAd decreased interstitial edema and inflammatory cell infiltration. These results
suggest that gAd protects against PQ‑induced lung injury by
mitigating oxidative/nitrative stress. Furthermore, gAd may
be a potential therapeutic agent for PQ‑induced lung injury,
and further pharmacological studies are therefore warranted.
Introduction
Paraquat (1,1'‑dimethyl‑4,4'‑bipyridinium dichloride; PQ) is
a widely‑utilized non‑selective herbicide for the control of
broadleaf weed. Available therapies for PQ poisoning lack
efficacy, and it is a major cause of herbicide‑related mortality,
which occurs due to respiratory failure secondary to lung
injury (1). Although the specific mechanisms of PQ toxicity
have not been fully defined, it is hypothesized that PQ toxicity
involves the generation of reactive oxygen species (ROS),
leading to subsequent oxidative stress, which results in cell
death and lung tissue damage (1,2). Antioxidants that directly
inhibit ROS generation have been proposed as possible therapeutic agents in PQ‑induced lung injury. However, traditional
antioxidants, such as glutathion and vitamin C, have failed to
protect against the characteristic pathological lung changes
or mortality observed in PQ poisoning (1). Therefore, mechanisms other than oxidative stress may also be responsible
for the pulmonary toxicity of PQ. The identification of such
mechanisms may yield insight into the development of novel
therapeutic agents and is an important area of research.
Adiponectin (also termed Acrp30, AdipoQ and GBP28)
is a protein predominantly secreted from adipose tissue (3‑5).
Primary sequence analysis has revealed that full-length
adiponectin has four main domains, with the globular segment
(gAd) at the carboxy terminus being much more potent than
the full protein (6,7). Adiponectin has been demonstrated to
exhibit anti‑oxidative and anti‑inflammatory effects (8). The
mechanisms of its actions are varied and depend upon the site
of activity. In endothelial cells, adiponectin enhances nitric
oxide (NO) production, suppresses the production of ROS and
protects against inflammation mediated by hyperglycemic
states or tumor necrosis factor, via activation of AMP‑activated
protein kinase and cyclic AMP‑dependent protein kinase
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signaling cascades (9). It was hypothesized that globular
domain adiponectin (gAd) may protect against PQ‑induced
lung injury by attenuating oxidative/nitrative stress.
The present study aimed to determine whether gAd protects
against PQ‑induced pulmonary injury in BALB/c mice and
to determine the underlying mechanism or mechanisms of
action. Ultimately the aim would be to assess the potential of
adiponectin as a novel therapeutic agent in PQ‑induced lung
injury.
Materials and methods
Materials. PQ was obtained from Tokyo Kasei Kogyo Co.,
Ltd. (Tokyo, Japan). Recombinant mouse gAd was obtained
from Adipobiotech Inc. (Beijing, China). Enzyme‑linked
immunosorbent assay (ELISA) kits for 3‑Nitrotyrosine
(3‑NT) were obtained from Abcam (Cambridge, MA, USA).
8‑hydroxy‑2‑dydeoxy guanosine (8‑OHdG) EIA and superoxide dismutase (SOD) assay kits were obtained from Cayman
Chemical Co. (Ann Arbor, MI, USA). Dihydroethidium (DHE)
probes were obtained from Merck Millipore (Darmstadt,
Germany). Malondialdehyde (MDA) EIA kits were obtained
from BioVision, Inc, (Milpitas CA, USA). The NO ELISA kit
was obtained from 4A Biotech Co., Ltd. (Beijing, China).
Animals and treatment. Male BALB/c mice were obtained
from Dossy Biological Technology Co., Ltd. (Chengdu, China).
They were housed at 22±2˚C in a humidity‑controlled room
with free access to fresh water and standard laboratory food.
Following 1 week of conditioning in a 12 h light/dark cycle,
eighty male mice were randomly divided into four groups: (i)
Control group (saline injection); (ii) PQ + low‑gAd group (PQ
exposure combined with gAd pre‑treatment at 500 µg/kg by
tail vein injection at 12 and 36 h prior to PQ administration);
(iii) PQ + high‑gAd group (PQ exposure combined with gAd
pre‑treatment at 1000 µg/kg by tail vein injection at 12 and
36 h prior to PQ administration); and (iv) PQ (20 mg/kg)
group, intraperitoneal administration (IP). The dose for
high/low gAd was determined from preliminary experiments
(data not shown). Mice were anesthetized with 50 mg/kg
pentobarbital (Hanlim Pharm. Co. Ltd., Seoul, Korea), IP.
Serum and pulmonary samples were collected at 3, 6, 12,
24 and 72 h post‑PQ injection. The study was conducted in
accordance with the ethical standards in the 1986 Directive
86/609/EEC, European Convention for the Protection
of Vertebrate Animals Used for Experimental and other
Scientific Purposes, and the Guiding Principles in the Use of
Animals in Toxicology, adopted by the Society of Toxicology
in 1989. The study was approved by the Committee on the
Ethics of Animal Experiments of the Sichuan University
(permit no. 26).
Histopathological assessment of pulmonary tissue.
Pulmonary tissue, fixed in 10% neutral‑buffered formalin,
was blocked in paraffin using an automated processor (Leica,
Nussloch，Germany), with graded alcohol, xylene and
paraffin. Sections (4 µm) were stained using hematoxylin and
eosin. Digital images of the stained glass slides were obtained
using a ScanScope Digital slide scanner (Aperio Technologies,
Inc., Vista, CA, USA) at a magnification of x100.

Measurement of superoxide anion in pulmonary tissue.
Lung segments obtained from control and PQ‑treated mice
were embedded in tissue freezing medium (Tris‑buffered
saline; Thermo Fisher Scientific, Waltham, MA, USA).
Following freezing, 30‑µm segments were cut, and mounted
and cover‑slipped on glass slides. Sections were treated with
2 µmol/l DHE in dimethyl sulfoxide buffer. Slides were
incubated in a light‑protected chamber at 37˚C for 30 min.
Ethidium‑stained tissue was observed by inverted fluorescent microscopy at a magnification of x100 (Olympus IX71,
Olympus, Tokyo, Japan) following excitation (485 nm) and
emission (535 nm). Control and PQ‑treated pulmonary samples
were processed and imaged in parallel.
Measurement of pulmonary tissue MDA, SOD, NO and
8‑OHdG levels, and blood 3‑NT levels. Pulmonary tissue
levels of MDA, SOD, NO and 8‑OHdG, and blood levels of
3‑NT from control and PQ‑treated mice were determined
using ELISA kits, according to the manufacturer's instructions.
Statistical analysis. All values are expressed as the
mean ± standard deviation. Comparisons between groups at
each time point were made by one‑way analysis of variance,
followed by Student‑Newman‑Keul's test. P<0.05 was considered to indicate a statistically significant difference.
Results
gAd attenuated PQ‑mediated pulmonary interstitial edema
and inflammatory cell infiltration in a dose‑dependent
manner. Compared with the control group (Fig. 1A), PQ
administration caused acute injury to pulmonary tissue, as
demonstrated by the interstitial edema and inflammatory cell
infiltration (lymphocytes and histiocytes) observed in the
alveolar space and septum (Fig. 1B). Pre‑treatment with gAd
inhibited these changes (Fig. 1C and D) in a dose‑dependent
manner.
gAd reduced PQ‑induced pulmonary oxidative injury in
a dose‑dependent manner. Three series of experiments
were performed to determine the effects of PQ and gAd on
oxidative stress in the mouse lung. In the first series, in situ O2•‑
generation was detected by DHE staining. Weak DHE staining
was observed in the pulmonary tissue of control animals,
indicating the basal pulmonic O2•‑ production (Fig. 2A). The
staining was significantly intensified in mice subjected to PQ
administration (Fig. 2B). By contrast, gAd (at high and low
doses, Fig. 2C and D) decreased this augmented staining.
In the second series of experiments, pulmonary tissue MDA
content was found to be significantly increased in mice subjected
to PQ administration at as early as 3 h following initial PQ
exposure (Fig. 3). This increase was eliminated from 6 to 72 h
following the initial PQ exposure, by pre‑treatment with gAd.
In the third series of experiments, pulmonary SOD levels
were found to be significantly increased at all time points
measured in animals subjected to PQ administration compared
with the control group (Fig. 4). Notably, the augmented SOD
activity was further amplified by pre‑administration of gAd at
3 h, although it was decreased from 6 to 72 h, in accordance
with the trend in MDA levels.
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Figure 1. Effect of gAd pre-treatment on pulmonary edema and inflammatory
cell infiltration in control animals or PQ-exposed animals, treated with vehicle
or gAd (high‑dose or low‑dose) 24 h prior to PQ injection. (A) Control group;
(B) PQ (20 mg/kg) group; (C) high‑dose gAd (1000 µg/kg); and (D) low‑dose
gAd (500 µg/kg). Values represent the mean ± standard error of the mean of
four parallel measurements. gAd, globular domain adiponectin; PQ, paraquat.
Stain, hematoxylin and eosin; magnification, x100.
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Figure 3. Effect of gAd pretreatment on pulmonary MDA level in control
animals or PQ‑exposed animals, treated with vehicle or gAd (high‑dose or
low‑dose) at 0, 3, 6, 12, 24 and 72 h after PQ injection. MDA levels were
determined by an enzyme‑linked immunosorbent assay. Values represent the
mean ± standard error of the mean of four parallel measurements. *P<0.05,
compared with controls and #P<0.05, compared with the PQ group. gAd,
globular domain adiponectin; MDA, malondialdehyde; PQ, paraquat.

Figure 4. Effect of gAd pre-treatment on pulmonary SOD level in control
animals or PQ‑exposed animals, treated with vehicle or gAd (high‑dose or
low‑dose) at 0, 3, 6, 12, 24 and 72 h following PQ injection. SOD levels were
determined by an enzyme‑linked immunosorbent assay. Values represent the
mean ± standard error of the mean of four parallel measurements. *P<0.05,
compared with controls and #P<0.05, compared with the PQ group. gAd,
globular domain adiponectin; SOD, superoxide dismutase; PQ, paraquat.

Figure 2. Effect of gAd pre-treatment on pulmonary superoxide anions in the
lungs from control animals or PQ-exposed animals, treated with vehicle or
gAd (high‑dose or low‑dose) 24 h prior to PQ injection. (A) Control group;
(B) PQ (20 mg/kg) group; (C) high-gAd (1000 µg/kg); and (D) low-gAd
(500 µg/kg). Values represent the mean ± standard error of the mean of four
parallel measurements. gAd, globular domain adiponectin; PQ, paraquat.
Stain, dihydroethidium; magnification, x100.

gAd reduced PQ‑induced pulmonary nitrative injury in a
dose‑dependent manner. NO production was significantly
increased in PQ‑exposed mice compared with the control
group. This augmentation was significantly reduced in
gAd‑pre‑treated mice compared with the PQ group (Fig. 5).
As a consequence of the induced NO production, blood 3‑NT
levels were also increased in the PQ‑exposed mice compared
with the control group. gAd administration decreased the
blood 3‑NT level, particularly from 24 to 72 h following
PQ‑exposure (Fig. 6).
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Figure 5. Effect of gAd pretreatment on pulmonary NO level in control
animals or PQ‑exposed animals, treated with vehicle or gAd (high‑dose or
low‑dose) at 0, 3, 6, 12, 24 and 72 h following PQ injection. NO levels were
determined by an enzyme‑linked immunosorbent assay. Values represent the
mean ± standard error of the mean of four parallel measurements. *P<0.05,
compared with controls and #P<0.05, compared with the PQ group. gAd,
globular domain adiponectin; NO, nitric oxide; PQ, paraquat.

Figure 6. Effects of gAd pretreatment on blood 3-NT level in control animals
or PQ‑exposed animals, determined by an enzyme‑linked immunosorbent
assay at 0, 3, 6, 12, 24 and 72 h. Values represent the mean ± standard error
of the mean of four parallel measurements. *P<0.05, compared with controls
and #P<0.05, compared with the PQ group. gAd, globular domain adiponectin; 3‑NT, 3‑nitrotyrosine; PQ, paraquat.

Similarly, a marked increase in pulmonary 8‑OHdG levels
was observed in PQ‑exposed mice compared with the control
group. The increase was decreased by gAd pre‑treatment to
a degree at all time points measured, and this reduction was
significant compared with the PQ group at 72 h (Fig. 7).
Discussion
Previous experimental and clinical studies have demonstrated
that PQ directly contributes to lung injury by inducing inflammation, edema and fibrosis (10‑13). In the present study, gAd
pre‑treatment mitigated the pathological changes induced

Figure 7. Effects of gAd pretreatment on pulmonary 8-OdGH in control
animals or PQ‑exposed animals, determined by an enzyme‑linked immunosorbent assay at 0, 3, 6, 12, 24 and 72 h. Values represent the mean ± standard
error of the mean of four parallel measurements. *P<0.05, compared with
controls and #P<0.05, compared with the PQ group. gAd, globular domain
adiponectin; 8‑OdGH, 8‑hydroxy‑2‑dydeoxy guanosine; PQ, paraquat.

by PQ in a dose‑dependent manner. This provides evidence
that the adipocytokine, adiponectin, which is known to have
antidiabetic (14), anti‑atherogenic (15), antitumor (16) and
anti‑inflammatory properties (17,18), also exerts a pulmonary
protective effect against PQ‑induced injury.
The current study indicated that the possible mechanisms
by which gAd relieves PQ‑induced lung injury may be attributed to two effects. gAd protects mice against PQ‑induced
lung injury by attenuating oxidative stress. In addition, gAd
protects against PQ‑induced lung injury by mitigating nitrative stress.
PQ is a toxic herbicide that particularly affects the lungs,
since the pulmonary polyamine uptake system preferentially
recruits PQ, resulting in a 6‑10 fold increase in lung levels
compared with the plasma (19,20). PQ is known to induce
alveolar collapse and fibrosis (21). Such effects are due to
the imbalance between the formation and scavenging of
ROS (1,2,22). ROS overproduction damages cell membranes,
resulting in lipid peroxidation, for which MDA levels serve as
a proxy measurement (23). SOD is a mammalian enzymatic
defense system, which protects against oxidative injury by
scavenging excess O2‑. It also indirectly reflects the level of
lipid peroxidation (24). The present study demonstrated that
PQ significantly increases MDA production and activates
SOD, which was consistent with a previous study (25) This
suggests that PQ simultaneously stimulates oxidative stress
injury and anti‑oxidative defenses to ameliorate lipid peroxidation.
Consistent with previous reports, adiponectin potently
scavenges free radicals, leading to the inhibition of lipid
peroxidation (6). In the current study, it was demonstrated
that gAd administration 12 and 36 h prior to PQ exposure
significantly attenuated O2‑ generation and MDA production.
To the best of our knowledge, this study provides the first
direct evidence supporting the hypothesis that adiponectin
modulates antioxidant defense mechanisms in the lung, and
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could thus offer protection against PQ‑induced lung damage
via attenuation of oxidative and nitrative stresses.
Contrary to findings from previous studies (26,27), gAd
pre‑treatment at high or low doses only augmented SOD
activities at 3 h following initial PQ exposure. By contrast,
SOD activity was lower in the gAd groups compared with the
PQ group following 6 to 72 h. There are a number of possible
explanations for this effect. The most plausible of these is that
gAd may stimulate anti‑oxidative SOD activity in a burst‑like
manner, which would diminish ROS and MDA levels such
that the higher levels of SOD producing the anti‑oxidant effect
were no longer required. An alternative explanation is that the
short half‑life (~13-17.5 h) of gAd in circulation (28) may limit
its anti‑oxidative properties over a prolonged period.
Other than ROS, reactive nitrogen species (RNS), including
NO and ONOO ‑, mediate nitrative stress via the nitration of
various biomolecules, including proteins, lipids and nucleic
acids (29). Accumulating evidence has demonstrated that PQ
augments NO and ONOO ‑ production, suggesting that RNS
are also involved in PQ‑mediated pulmonary injury (30‑33).
The current study showed that PQ significantly increased
NO production, which emphasized the pathophysiological
importance of NO in PQ‑mediated lung injury. In contrast
to its effects in an endothelial model (34), pre‑treatment with
gAd significantly reduced NO production in PQ‑exposed mice
lung. A possible explanation may be that gAd causes different
effects in different cells or tissues under different stimulation.
Excess NO reacts with O2‑ to produce ONOO ‑ (35,36).
ONOO ‑ is a highly toxic reactive species, which nitratively
modifies various proteins, for example, changing tyrosine to
3‑NT (37). ONOO‑ also injures DNA via a number of mechanisms, including the formation of 8‑OHdG (38). The present
study demonstrated an increase in 8‑OHdG levels in lung
tissue from 6 to 72 h, and increased 3‑NT from 12 to 72 h, in
PQ‑exposed mice. These results provide additional evidence
in support of the hypothesis that nitrative stress is involved in
PQ‑mediated injury (39). gAd pre‑treatment markedly attenuated 3‑NT production at 24 and 72 h, and decreased 8‑OHdG
after 72 h. To the best of our knowledge, this is the first evidence
demonstrating that adiponectin protects against PQ‑mediated
lung injury by attenuating peroxynitrite‑induced protein nitration and DNA damage via a reduction in nitrative stress.
In conclusion, the present study demonstrates that gAd
protects against PQ‑induced lung injury in a BALB/c
mouse model, by attenuating oxidative/nitrative stress in a
dose‑dependent manner. Adiponectin is therefore a potential
therapeutic agent against PQ‑induced lung injury, for which
no efficacious treatment currently exists. Clarification of the
precise signaling mechanisms involved in the amelioration
of oxidative/nitrative stress by adiponectin requires further
investigation. In addition, further studies are required in order
to assess the effect of gAD given with and following PQ
administration, as the current study, which only examined the
effect of pre-treatment with gAd, does not accurately mimic
true clinical scenarios.
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